TREE NEWS update: Shanghai RAAS Biotech’s deputy chairman and general manager Xu Jun said on September 28 that the company’s proposed acquisition of Boehringer Ingelheim Biopharmaceuticals (China) is a strategic move to build out commercialization capacity for innovative drugs. Xu said the R&D push will be funded by steady cash flow from its blood products business on a rolling basis, and the company will not pour all blood-products profits into new drug development at once.
Shanghai RAAS Defends CDMO Plant Acquisition to Bolster Innovative Drug Capabilities
AI take
The notable point is the funding structure: Shanghai RAAS is explicitly tying its innovative-drug ambitions to blood-products cash flow rather than to a single large bet, a more conservative posture than the sector's usual narrative of aggressive pipeline spending. The acquired CDMO site functions as commercialization capacity, not just R&D, which suggests the company is positioning for late-stage manufacturing rather than early discovery. Whether that rolling, self-funded model can support the timeline innovative-drug development demands is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
43m ago
Hang Seng Tech Index Falls as Much as 1.8%, Hits Year Low of 4,217.81
1h ago
Hengrui Pharmaceuticals Shares Jump Over 3% in Sharp Rally
1h ago
MSCI Asia-Pacific Index Falls 1% to 273.83
2h ago
Changan Auto Sets Up AD Synergy Dept for Deepal and Avatr
2h ago
South Korea’s KOSPI Falls 1% Intraday
2h ago
China Stocks Close Morning Session Mixed; Shanghai Composite Up 0.08%